GTN

Quick links to important sections

GTN

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of GTN

Property Description
Active ingredient Nitroglycerin (Glyceryl trinitrate)
Key Forms Sublingual tablets, Sublingual spray, Transdermal patches
Pharmacological class Organic nitrate, Vasodilator, Antianginal agent
General Purpose To manage acute or prophylactic discomfort related to heart oxygen deprivation
Origin Synthetic compound

Glyceryl trinitrate (GTN) is the chemical name and common abbreviation for the drug Nitroglycerin, classified as an organic nitrate and a potent vasodilator. This synthetic compound is recognized as a single-ingredient, Prescription-Only Medicine (POM). It is available in various pharmaceutical preparations to ensure targeted delivery, including sublingual tablets and sprays.

GTN’s Classification as an Antianginal Agent

GTN is classified as an antianginal agent because its primary therapeutic role is to relieve discomfort associated with myocardial ischemia—insufficient oxygen supply to the heart muscle. Organic nitrates like Nitroglycerin are used to reduce episodes of chest discomfort by reducing cardiac oxygen requirements. This indicates the medicine helps ease cardiac strain by balancing oxygen supply and demand.

As a vasodilator, Nitroglycerin is converted in the body into the signaling molecule nitric oxide, which causes the relaxation of smooth muscles within blood vessel walls. The primary action is venodilation, which significantly reduces the heart’s overall workload by decreasing the volume and pressure of blood returning to it (preload reduction).

How Does Nitroglycerin Compare to Other Nitrates?

Nitroglycerin is differentiated from other organic nitrates, such as Isosorbide mononitrate, primarily by its diverse range of rapid-acting and long-acting formulations. Its various preparations are used for tailoring treatment to the need for either immediate or sustained pharmacological effect. It is available in rapid-acting forms like sublingual spray, and long-acting preparations such as transdermal patches for continuous relief.

Regulatory References

  1. Nitroglycerin - StatPearls - NCBI Bookshelf

What side effects are possible with GTN?

Possible Side Effects and Safety Information

The official safety profile for Glyceryl Trinitrate (GTN) is documented by governmental regulatory agencies and primarily reflects adverse reactions stemming from its potent vasodilatory action. These effects are formally classified by frequency and body system.


Frequency-Classified Adverse Reactions

The frequency framework often classifies effects as follows:

  • Very Common: The most frequently reported adverse reaction is headache, which is often dose-related and may be more noticeable at the initiation of therapy, but can subside with continued use.
  • Common: Adverse effects such as dizziness, hypotension (low blood pressure), flushing, nausea, and vomiting are commonly observed.
  • Uncommon/Rare: Less frequent effects include syncope (fainting), circulatory collapse, and specialized skin reactions such as contact dermatitis.

System-Organ Classes and Serious Reactions

Adverse effects are formally grouped into System-Organ Classes (SOC). The most affected systems include the Nervous System (e.g., headache, dizziness) and Vascular Disorders (e.g., hypotension).

Serious Adverse Reactions officially listed in regulatory documents include instances of severe hypotension and circulatory failure/shock. A rare but serious concern documented is methemoglobinemia.


Regulatory Safety Constraints

The official labeling includes specific safety restrictions and population constraints.

  • Absolute Contraindication: GTN is strictly contraindicated for use with Phosphodiesterase type 5 (PDE5) inhibitors (such as sildenafil or tadalafil), as this combination carries a high risk of severe, life-threatening hypotension.
  • Population Constraints: Safety constraints are noted for patients with pre-existing conditions like severe anemia or increased intracranial pressure. Additionally, official documents state that safety and effectiveness have not been established for pediatric use.

Overdose and Emergency Response

The official regulatory profile for a Glyceryl Trinitrate (GTN) overdose details the progression from specific manifestations to life-threatening emergencies. Documented initial signs of overdose can include a persistent throbbing headache, vertigo, dizziness, and visual disturbance. Gastrointestinal effects such as nausea, vomiting, and abdominal colic are also described in official labeling.

The most serious outcomes are severe cardiovascular events. Overdose exposure can result in profound hypotension (dangerously low blood pressure), leading to circulatory collapse, shock, convulsions, or coma. A critical physiological outcome is Methaemoglobinaemia, which may present with cyanosis.

Regulatory instructions mandate specific actions. Immediate medical attention is required if acute, life-threatening symptoms such as seizures or trouble breathing occur, or if the patient becomes unresponsive. Emergency medical assistance must also be sought if symptoms persist after the maximum designated number of doses within the labeled timeframe. Management in a hospital setting is symptomatic and supportive, including measures like elevation of extremities and volume expansion to correct severe hypotension. Continuous monitoring of vital signs and the ECG is required.

Therapeutic Uses of GTN

What GTN Treats: Main Uses and Benefits

GTN (Glyceryl Trinitrate) is generally used for symptomatic management, providing supportive relief across key domains of chest discomfort. It is used for the management of symptoms associated with acute and episodic changes due to coronary artery disease.

The medication is commonly used to help with symptoms related to physical discomfort and in conditions involving episodic or fluctuating manifestations, such as stable and unstable angina. It is relevant in clinical settings where short-term symptomatic assistance is needed during phases when symptoms become more noticeable.

It is applied in scenarios where additional management of discomfort is required, especially during episodes of sudden symptom escalation or when symptoms create noticeable physiological strain. The medication generally plays a role in managing the overall symptom burden. One common description of its function is that it:

“supports the patient during difficult episodes by easing distress.”

Quick Fact: Symptom Support Summary

GTN helps address symptom clusters that may become intense or disruptive, supporting general well-being during symptomatic phases and assisting with maintaining functional stability.

Eligibility and Restrictions for Use

Glyceryl Trinitrate (GTN) is intended for use in adults. Official regulatory documents define specific populations who must not use the medicine and others who require special caution.

Contraindications (Must Not Use)

GTN is strictly contraindicated in patients with a known hypersensitivity to the medicine or other nitrates. It must not be used concurrently with Phosphodiesterase-5 (PDE-5) inhibitors (e.g., sildenafil, vardenafil, tadalafil) or soluble guanylate cyclase (sGC) stimulators (e.g., riociguat) due to the risk of severe, life-threatening hypotension.

Use is also prohibited in patients with severe hypotension, severe anemia, cerebral hemorrhage, increased intracranial pressure (such as from a recent head trauma), circulatory failure or shock, constrictive pericarditis, or hypertrophic obstructive cardiomyopathy (HOCM).

Restricted Populations

Pediatric Use: The safety and effectiveness of GTN have not been established in patients under 18 years of age; therefore, its use is not recommended in children.

Pregnancy and Lactation: Use during pregnancy and breastfeeding is not recommended because safety data are not fully established.

Condition-Specific Caution: Special caution and additional monitoring are required for patients with severe impairment of renal or hepatic function and for older adults.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Glyceryl Trinitrate (GTN) has documented interaction patterns that are formally classified in regulatory prescribing information, primarily relating to its potent vasodilatory action and effects on the metabolism of co-administered medicines.


Official Interaction Classifications

Prohibited Combinations (Contraindicated)

Co-administration with Phosphodiesterase-5 (PDE-5) Inhibitors (including sildenafil, tadalafil, and vardenafil) is strictly contraindicated. This combination carries a risk of severe and sustained hypotension (a dangerous drop in blood pressure) due to the potentiation of vasodilatory effects. The co-administration of Soluble Guanylate Cyclase (sGC) Stimulators (such as riociguat) is also contraindicated for the same risk of profound hypotension.


Pharmacodynamic and Exposure Interactions

Additive Hypotension: Concomitant use with other antihypertensive drugs (including beta-blockers and calcium channel blockers) may result in additive hypotensive effects. Similarly, the consumption of alcohol is officially restricted as its vasodilating effects are additive to those of GTN, potentially causing hypotension.

Exposure and Efficacy Alteration: Official labeling documents that co-administration with aspirin can increase GTN plasma concentrations. Furthermore, intravenous GTN has been reported to reduce the anticoagulant effect of Heparin and decrease the thrombolytic effect of Alteplase, requiring specific monitoring when these agents are used together. GTN also reduces the first-pass metabolism of dihydroergotamine, increasing its oral exposure.

Regulatory documents state that using a PDE-5 inhibitor within a few days of GTN is not recommended, underscoring the timing-based restriction associated with this contraindicated class.

Mechanism of Action

The Mechanism of Prodrug Bioactivation

Glyceryl Trinitrate (GTN) functions as an inactive prodrug, requiring conversion inside vascular smooth muscle cells. This process is mediated primarily by the enzyme Mitochondrial Aldehyde Dehydrogenase 2 ( ALDH2), which catalyzes the release of the short-acting signaling molecule, Nitric Oxide ( NO).


The NO/ cGMP Signaling Cascade

The released NO activates the intracellular enzyme Soluble Guanylate Cyclase ( sGC), initiating the synthesis of the second messenger, cyclic Guanosine Monophosphate ( cGMP). Increased cGMP concentration triggers a molecular cascade that causes the dephosphorylation of Myosin Light Chains (MLC). This cessation of the contractile protein interaction leads directly to the relaxation of vascular smooth muscle.


Hemodynamic Effect: Reducing Cardiac Preload

The muscle relaxation effect is preferentially observed in the veins (capacitance vessels), leading to peripheral venous pooling of blood. This results in a reduction of the volume and pressure of blood returning to the heart, a key hemodynamic measure known as preload. The mechanism of preload reduction directly and efficiently decreases ventricular wall tension and Myocardial Oxygen Demand ( MVO2).

Dosage and Administration Information

Instruction Map: How GTN is Used

Glyceryl Trinitrate (GTN) is administered through distinct routes and schedules based on whether the intended effect is for rapid relief or sustained prophylaxis. The Sublingual route is designated for acute, as-needed (PRN) use, employing immediate-release forms such as metered sprays (e.g., 400 mcg/spray) or tablets (e.g., 0.4 mg).

Administration Protocols

The protocol for acute episodes dictates that a single dose is administered at the onset, which may be repeated approximately every 5 minutes. This sequence is limited to a maximum of three doses within a 15-minute period. Procedural instructions emphasize that the patient should be in a sitting position during administration, and the sublingual dose must not be swallowed or rinsed from the mouth for several minutes to ensure proper absorption.

For prophylactic management, GTN is typically administered via the Transdermal route using patches that deliver a continuous rate (e.g., 0.4 mg/hr). This long-acting administration is structured around a cyclic schedule to maintain effectiveness. The administration schedule involves a daily application followed by a nitrate-free interval of 10 to 12 hours. Administration specifics include applying the patch to clean, non-irritated skin on the upper body, rotating the site daily, and strictly prohibiting the cutting or trimming of the patch. The drug's indication is not typically applicable to children.

Recent Clinical Evidence

GTN: Recent Clinical Evidence

Evidence for Use in Stable Angina Pectoris

Research examining Glyceryl Trinitrate (GTN) was studied in conditions characterized by fluctuating or episodic manifestations, such as chronic anginal symptoms. This research primarily uses Randomized Controlled Trials (RCTs) to explore whether it affects acute chest discomfort and to assess its potential role in prophylactic management. Researchers monitored the change in frequency of anginal episodes and the time until patients reported a change in their discomfort. Studies also examined outcomes reflecting daily functioning or activity level, specifically monitoring changes in exercise performance and the time to symptom onset during physical activity.

Findings describe patterns observed in these studies, particularly for the quick-acting forms, which help contextualize how patients reported their experience of acute symptom change. For the long-acting forms, studies reported varying measurements of patient exercise tolerance, and some studies described patterns such as a reduced measured response over time. Follow-up durations were limited in many studies, meaning long-term effects are not fully established regarding sustained functional capacity.

Evidence for Use in Acute Episodes and Conditions

GTN was studied for its role in conditions associated with acute or disruptive episodes, such as during Acute Coronary Syndromes (ACS) and episodes of Acute Hypertensive Heart Failure. The research landscape contains clinical trials and observational cohort studies. For ACS, researchers tracked outcomes such as in-hospital status, all-cause mortality, and the incidence of Major Adverse Cardiac Events (MACE). In acute heart failure, studies examined outcomes capturing phases of heightened symptom activity, such as the resolution of severe breathlessness and changes in blood pressure during the acute phase of treatment.

For both acute conditions, data are still emerging regarding the overall impact on long-term outcomes. For ACS, much of the research on long-term outcomes comes from older studies, and some findings were mixed regarding patterns related to MACE and mortality. For acute heart failure, evidence is limited to the short-term stabilization phase, and the comparative evidence is lacking from large, modern RCTs that focus solely on the measured effect of GTN.

Studies Addressing Long-Term Outcomes and Durability of Response

Studies for GTN primarily focus on research exploring short-term symptom changes and functional capacity. Research highlights changes measured during the study period, but there is limited information for long-term outcomes that track effects over many years. Definitive conclusions about the long-term persistence of observed changes and long-term health impact are not fully established.

Evidence in Specific Patient Groups and Uncertainties

Research was observed in varying patient groups, but data for certain groups remain insufficient. For instance, some observational cohort studies examined populations including age-stratified groups such as elderly patients (ge 75 years). Findings in these groups have sometimes been mixed, meaning subgroup findings are uncertain. Overall, the results apply only to the populations studied. Furthermore, patterns related to the development of nitrate tolerance were observed in some studies, and the evidence quality varies across studies, particularly in acute settings where much of the data comes from older studies.

Key Studies & References

  1. Nitroglycerin Tablets, USP - DailyMed (FDA Labeling)

Frequently Asked Questions (FAQ)

Common questions about GTN (FAQ)


Q: How quickly is GTN supposed to start working?

According to official product information for the sublingual forms (tablets or spray), the medication is typically expected to provide acute relief from chest discomfort within 1 to 5 minutes. This rapid onset supports the drug's indicated use for acute symptoms.


Q: How long does the effect of GTN usually last?

The effect of a single sublingual dose is typically short-acting, lasting only a few minutes. Official administration guidelines indicate that if acute relief is not achieved, the dose can be repeated as directed by a healthcare provider for acute use.


Q: Can GTN stop working over time?

Studies and official product information indicate that the body may develop nitrate tolerance, meaning the drug's effect may be reduced with continuous, uninterrupted use. Regulatory documents describe strategies to help prevent this, such as the use of a required drug-free interval (typically 10 to 12 hours) with long-acting forms.


Q: Is a headache always a side effect of GTN?

No, official safety information states that headache is the most frequently reported side effect, often experienced at the start of therapy. It is listed as very common and is often considered a marker of the drug's activity, but it does not occur in every patient. The severity of the headache may also subside with continued use.


Q: Why does GTN sometimes cause a flushing sensation or redness?

The medicine works primarily by causing the relaxation of vascular smooth muscle (vasodilation), which leads to the widening of blood vessels. This powerful physical action is the underlying cause of common side effects like flushing or redness.


Q: Is GTN suitable for older adults?

Official documents note that older adults may require special caution and additional monitoring during treatment. Furthermore, research findings observed in elderly patient groups are sometimes described as mixed. Suitability for any individual, including older adults, is determined by a healthcare provider.


Q: Does GTN expire, and if so, what happens after the expiration date?

Yes, the tablets are sensitive to moisture, light, and heat, and they lose potency over time. Official instructions emphasize keeping sublingual tablets in their original glass container and tightly capped to prevent this loss of effectiveness. Expired medication is generally recommended to be safely discarded, often through a pharmacy or drug take-back program.


Q: Can using GTN affect driving or operating machinery?

Yes, because GTN’s primary action is to lower blood pressure, it may cause side effects such as dizziness, hypotension (low blood pressure), or even fainting. Official warnings indicate that patients who experience these effects may have impaired ability and should exercise caution regarding driving or operating machinery.


Q: Do studies show that GTN is effective for its main use?

GTN is indicated by regulatory agencies for the acute relief or prophylaxis (prevention) of angina pectoris (chest discomfort) due to coronary artery disease. This official indication means the drug has been reviewed and cleared for use in this context.


Q: Does using GTN change the outcome for people with heart conditions?

The available research base primarily addresses the short-term change in symptoms and functional capacity (like exercise tolerance). Official reviews indicate that data regarding the drug's long-term impact on major outcomes like all-cause mortality is often described as limited, and findings are sometimes mixed.


Q: Are there any food or drink restrictions while using GTN?

Regulatory information states that alcohol consumption is restricted because its vasodilating effects may be additive to those of GTN, potentially causing severe low blood pressure (hypotension). No specific food restrictions are typically listed.


Q: Is GTN considered a high-risk medication?

GTN is classified as a Prescription-Only Medicine (POM). Official labeling includes absolute contraindications with certain drug classes (like PDE-5 inhibitors) due to the risk of severe and life-threatening low blood pressure (hypotension) or circulatory failure.


Q: Are there different storage requirements for different GTN formulations?

Yes, there are differences. Sublingual tablets must be kept in the original glass container and have a limited stability period (often 8 weeks to 3 months) after being opened. Transdermal patches are noted to have specific instructions for safe disposal, which includes securing the patch.


Q: What does it feel like when GTN starts to work?

When the medication starts working, some patients may feel an immediate throbbing headache, which is officially described as a common marker of the drug's activity. Other sensations often felt immediately include flushing or, with the sublingual tablet or spray, a tingling or slight burning sensation in the mouth.


Q: Are there specific over-the-counter (OTC) medicines that interact with GTN?

Regulatory sources generally advise that Paracetamol (Acetaminophen) is safe to take with GTN. However, caution should be exercised with certain non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen.


Q: Is it okay to use GTN with pain relievers like paracetamol or ibuprofen?

Paracetamol (Acetaminophen) is generally safe to use. However, official information suggests that non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen or aspirin should be used with caution, as they may potentially worsen angina in some patients.


Q: What should I do if I accidentally take too much GTN?

If you suspect an overdose or experience severe symptoms like extreme dizziness or weakness, immediate emergency medical attention is required. Official guidance emphasizes seeking help if acute chest pain persists after the maximum allowed dose is reached.


Q: If I miss a dose of my regular GTN, what are the general guidelines?

Official guidelines for a missed scheduled dose (e.g., a transdermal patch) describe scenarios where the dose may be applied when remembered or skipped, and advise against doubling the dose.


Q: Does GTN affect how my heart rate changes during activity?

GTN’s primary action is to cause widespread relaxation of blood vessels, which lowers blood pressure. This drop in blood pressure can sometimes lead to a slight and temporary increase in heart rate (tachycardia) as a compensatory response by the body.


Q: Why does GTN come in different strengths?

GTN is manufactured in different strengths (e.g., 0.3 mg, 0.4 mg, 0.6 mg tablets) to allow healthcare providers to adjust the dose based on the patient's individual medical needs, condition, and response to treatment.


Q: Is it normal to feel a tingling sensation when using the GTN tablet?

Yes, a common effect of the sublingual tablet or spray is a tingling or burning sensation in the mouth immediately upon application. This sensation is generally described as an expected effect, and its presence is noted in official information.


Q: Is it possible to become dependent on GTN?

Regulatory warnings mention that in cases of long-term, high-level continuous exposure to nitrates, such as in certain industrial settings, physical dependence may occur. This is the rationale behind prescribed therapies requiring nitrate-free intervals.


Q: Are there any known interactions between GTN and herbal supplements?

Official patient information states there is insufficient data to determine the safety of combining GTN with herbal remedies or complementary medicines. This is because these products are not regulated or tested for drug interactions in the same way as prescription medicines.


Q: Are there any warnings for people with glaucoma who use GTN?

Warnings may be noted for patients with glaucoma or conditions that increase pressure within the eye (intraocular pressure). GTN should be used with caution in this population, and closed-angle glaucoma may be listed as a contraindication in some regulatory documents.

How should GTN be stored and disposed of?

Official Storage and Disposal Requirements for Glyceryl Trinitrate (GTN)

Storage Component Official Requirement
Temperature Store at controlled room temperature, typically mathbf20 C to mathbf25 C mathbf(68 F to 77 F). Do not freeze and keep away from ignition sources.
Protection Keep in the original, tightly closed container and protect from mathbflight and mathbfmoisture.
Stability Sublingual tablets must be discarded mathbf8 weeks or no longer than three months after the bottle is first opened.
Child Safety Must be kept out of the sight and reach of children. Used transdermal patches must be safely mathbffolded and secured before disposal.
Disposal Return unused or expired GTN to a mathbfpharmacy or mathbfdrug take -back program for proper disposal. Do not dispose of in household trash or down the drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of GTN found in:

A-Z Index: